SALMON EVOLUTION ASA (SALME.OL) Stock Fundamental Analysis

Europe • Euronext Oslo • OSL:SALME • NO0010892094

4.89 NOK
+0.04 (+0.82%)
Last: Feb 6, 2026, 11:48 AM
Fundamental Rating

2

SALME gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 67 industry peers in the Food Products industry. Both the profitability and financial health of SALME have multiple concerns. While showing a medium growth rate, SALME is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year SALME has reported negative net income.
  • SALME had a negative operating cash flow in the past year.
  • In the past 5 years SALME always reported negative net income.
  • SALME had negative operating cash flow in 4 of the past 5 years.
SALME.OL Yearly Net Income VS EBIT VS OCF VS FCFSALME.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -200M -400M -600M -800M

1.2 Ratios

  • The Return On Assets of SALME (-5.18%) is worse than 80.60% of its industry peers.
  • With a Return On Equity value of -9.61%, SALME is not doing good in the industry: 79.10% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -5.18%
ROE -9.61%
ROIC N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
SALME.OL Yearly ROA, ROE, ROICSALME.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

  • With an excellent Gross Margin value of 51.20%, SALME belongs to the best of the industry, outperforming 86.57% of the companies in the same industry.
  • SALME's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SALME so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
SALME.OL Yearly Profit, Operating, Gross MarginsSALME.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • SALME does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SALME has been increased compared to 1 year ago.
  • SALME has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SALME has been reduced compared to a year ago.
SALME.OL Yearly Shares OutstandingSALME.OL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
SALME.OL Yearly Total Debt VS Total AssetsSALME.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

  • Based on the Altman-Z score of 0.58, we must say that SALME is in the distress zone and has some risk of bankruptcy.
  • SALME has a Altman-Z score of 0.58. This is amonst the worse of the industry: SALME underperforms 83.58% of its industry peers.
  • A Debt/Equity ratio of 0.58 indicates that SALME is somewhat dependend on debt financing.
  • SALME has a Debt to Equity ratio (0.58) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z 0.58
ROIC/WACCN/A
WACC7.83%
SALME.OL Yearly LT Debt VS Equity VS FCFSALME.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

2.3 Liquidity

  • SALME has a Current Ratio of 0.90. This is a bad value and indicates that SALME is not financially healthy enough and could expect problems in meeting its short term obligations.
  • SALME has a Current ratio of 0.90. This is in the lower half of the industry: SALME underperforms 76.12% of its industry peers.
  • A Quick Ratio of 0.51 indicates that SALME may have some problems paying its short term obligations.
  • The Quick ratio of SALME (0.51) is worse than 74.63% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.51
SALME.OL Yearly Current Assets VS Current LiabilitesSALME.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • SALME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -152.94%.
  • Looking at the last year, SALME shows a decrease in Revenue. The Revenue has decreased by -6.16% in the last year.
  • SALME shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 238.62% yearly.
EPS 1Y (TTM)-152.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-6.16%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%68.54%

3.2 Future

  • Based on estimates for the next years, SALME will show a very strong growth in Earnings Per Share. The EPS will grow by 81.13% on average per year.
  • SALME is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.13% yearly.
EPS Next Y-330.73%
EPS Next 2Y-6%
EPS Next 3Y50.21%
EPS Next 5Y81.13%
Revenue Next Year-27.75%
Revenue Next 2Y15.64%
Revenue Next 3Y39.62%
Revenue Next 5Y37.13%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SALME.OL Yearly Revenue VS EstimatesSALME.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
SALME.OL Yearly EPS VS EstimatesSALME.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • SALME reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SALME. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SALME.OL Price Earnings VS Forward Price EarningsSALME.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SALME.OL Per share dataSALME.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SALME's earnings are expected to grow with 50.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6%
EPS Next 3Y50.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SALME does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SALMON EVOLUTION ASA

OSL:SALME (2/6/2026, 11:48:49 AM)

4.89

+0.04 (+0.82%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)11-11
Earnings (Next)02-09
Inst Owners22.98%
Inst Owner ChangeN/A
Ins Owners2.16%
Ins Owner ChangeN/A
Market Cap2.26B
Revenue(TTM)376.56M
Net Income(TTM)-197.38M
Analysts86.25
Price Target7.82 (59.92%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-99.47%
Min EPS beat(2)-210.68%
Max EPS beat(2)11.74%
EPS beat(4)1
Avg EPS beat(4)-421.1%
Min EPS beat(4)-1265.05%
Max EPS beat(4)11.74%
EPS beat(8)3
Avg EPS beat(8)-219.15%
EPS beat(12)5
Avg EPS beat(12)-152.08%
EPS beat(16)9
Avg EPS beat(16)-106.45%
Revenue beat(2)0
Avg Revenue beat(2)-17.43%
Min Revenue beat(2)-18.01%
Max Revenue beat(2)-16.84%
Revenue beat(4)1
Avg Revenue beat(4)-19.2%
Min Revenue beat(4)-43.93%
Max Revenue beat(4)1.98%
Revenue beat(8)3
Avg Revenue beat(8)-14.52%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.36%
EPS NY rev (1m)0%
EPS NY rev (3m)-30.19%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.79%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-18.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.01
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS0.81
BVpS4.44
TBVpS4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.18%
ROE -9.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.2%
FCFM N/A
ROA(3y)-2.76%
ROA(5y)-2.34%
ROE(3y)-3.94%
ROE(5y)-3.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-11.83%
GM growth 5YN/A
F-Score2
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1184.8%
Cap/Sales 264.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.9
Quick Ratio 0.51
Altman-Z 0.58
F-Score2
WACC7.83%
ROIC/WACCN/A
Cap/Depr(3y)4495.02%
Cap/Depr(5y)15899.7%
Cap/Sales(3y)642.51%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-152.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-330.73%
EPS Next 2Y-6%
EPS Next 3Y50.21%
EPS Next 5Y81.13%
Revenue 1Y (TTM)-6.16%
Revenue growth 3Y238.62%
Revenue growth 5YN/A
Sales Q2Q%68.54%
Revenue Next Year-27.75%
Revenue Next 2Y15.64%
Revenue Next 3Y39.62%
Revenue Next 5Y37.13%
EBIT growth 1Y-443.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-56473.6%
EBIT Next 3Y1328.21%
EBIT Next 5Y475.69%
FCF growth 1Y-95.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.11%
OCF growth 3YN/A
OCF growth 5YN/A

SALMON EVOLUTION ASA / SALME.OL FAQ

What is the fundamental rating for SALME stock?

ChartMill assigns a fundamental rating of 2 / 10 to SALME.OL.


What is the valuation status of SALMON EVOLUTION ASA (SALME.OL) stock?

ChartMill assigns a valuation rating of 1 / 10 to SALMON EVOLUTION ASA (SALME.OL). This can be considered as Overvalued.


Can you provide the profitability details for SALMON EVOLUTION ASA?

SALMON EVOLUTION ASA (SALME.OL) has a profitability rating of 1 / 10.


What is the financial health of SALMON EVOLUTION ASA (SALME.OL) stock?

The financial health rating of SALMON EVOLUTION ASA (SALME.OL) is 1 / 10.


What is the earnings growth outlook for SALMON EVOLUTION ASA?

The Earnings per Share (EPS) of SALMON EVOLUTION ASA (SALME.OL) is expected to decline by -330.73% in the next year.